PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Uterine cervix neoplasm

Drugs in development · updated 30 October 2026

Uterine cervix neoplasm: drugs in development

As of 30 October 2026 there are 204 active clinical trials (recruiting or ongoing, phases I–III) on 224 drugs for uterine cervix neoplasm. 131 are experimental, that is not yet approved in the United States.

204Active trials
131Experimental drugs
13Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
CadonilimabAK104, CandonilimabIII6NCT04982237
CamrelizumabCarrelizumab, CarilizumabII–III5NCT06288373
Sacituzumab TirumotecanSKB264III5NCT07216703
JSKN033III2NCT07797153
NimotuzumabTheraloc®III2NCT06333821
TriapineIII2NCT02466971
9MW2821III1NCT06692166
LB1410II–III1NCT07177716
LB4330II–III1NCT07177716
RulonilimabII–III1NCT06755515
SHR-A2102III1NCT07418749
SocazolimabIII1NCT06459687
SYS6002III1NCT07230626
IparomlimabiparomilimabII6NCT07646301
ZimberelimabAB122, GLS-010II6NCT07424664
TuvonralimabII5NCT07646301
Izalontamab brengitecanBL-B01D1, BMS-986507I–II4NCT05803018
QL1706II4NCT07617818
AdebrelimabSHR-1316, AdebelimabI–II3NCT06859775
SerplulimabHLX10, Hetronifly®II3NCT07340489
AnlotinibAL3818, AnrotinibII2NCT05137171
IvonescimabAK112II2NCT06925724
SHR-A1811I–II2NCT06859775
TolinapantASTX660I–II2NCT02503423
AdavosertibAZD1775II1NCT02465060
ARV-6723I–II1NCT07749586
B1962II1NCT06724263
BAY2927088II1NCT06760819
Becotatug VedotinMRG003II1NCT07424664
BMS-936558-01I–II1NCT04895709
CediranibZemfirza®II1NCT04487587
CeralasertibAZD6738II1NCT04065269
ChemoradiotherapyII1NCT05872724
CobolimabTSR-022II1NCT06238635
Coenzyme Q10CoQ10I–II1NCT07668284
CVL237II1NCT07446049
DB-1311I–II1NCT05914116
Disitamab VedotinRC48-ADC, Disitamb VedotinII1NCT06155396
EnvafolimabKN035II1NCT05799469
ETX-636I–II1NCT06993844

Sorted by most advanced phase and number of active trials. Showing 40 of 131 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
PembrolizumabKEYTRUDA, MK-3475III35NCT07216703
CisplatinCis Platinum, CisplatineII–III34NCT06123884
CarboplatinCarboplatine, ParaplatinII–III22NCT06123884
PaclitaxelTaxol, PaxlitaxelII–III22NCT06123884
Bevacizumabavastin, MVASIII–III14NCT07472153
GemcitabineGemcitabin, GemzarIII7NCT07797153
LenvatinibLenvatinib Mesilate Capsules, LevatinibII–III6NCT07177716
DocetaxelTaxotere, Beizray®III5NCT07797153
PemetrexedAxtle®, Pemfexy®III3NCT07797153
TopotecanHycamtin®, Topotecan Hospira®III3NCT07797153
IrinotecanOnivyde, CPT-11III1NCT06459180
Tisotumab VedotinTivdak®III1NCT06459180
VinorelbineNavelbine®III1NCT06459180
NivolumabOpdivo, ONO-4538I–II9NCT06047379
AtezolizumabTecentriq, MPDL3280AI–II6NCT05944237

Sorted by most advanced phase and number of active trials. Showing 15 of 93 drugs.

All 224 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D002583 “Uterine Cervical Neoplasms”.

ItalianoFrançaisDeutsch